Silverstein H, Choo D, Rosenberg S I, Kuhn J, Seidman M, Stein I
Ear Research Foundation, Sarasota, FL 34239, USA.
Ear Nose Throat J. 1996 Aug;75(8):468-71, 474, 476 passim.
Intratympanic instillation of Depo-Medrol (80 mg/cc), dexamethasone ophthalmic solution (1 mg/cc), or dexamethasone intravenous (4 mg/cc) solution produces improvement of cochlear function in certain patients with Meniere's disease, autoimmune inner ear disease and sudden sensorineural deafness. Tinnitus improved in 47%, most often in patients with Meniere's disease (9 of 15; 60%). The SRT improvement of greater than 10 dB or SD greater than 15% was documented in 41% (average improvement in SRT: 15 dB; SD: 24%). Patients with tinnitus and bilateral sensorineural hearing loss (i.e., presbycusis) did not benefit from the treatment. Prior to treatment with intratympanic medication, laser assisted tympanostomy with middle ear exploration, using otoendoscopy to determine the status of the round window niche and remove mucosal folds, helps in making the round window membrane accessible to local application of drops. Placing Gelfoam into the round window niche under direct vision, and using a Venturi Bobbin tube in the tympanic membrane, appears to be a satisfactory method for delivering medication to the inner ear fluids. The medication can be injected by the physician through the tube into the middle ear, or the patient can perform self-treatment at home, placing medication in the external auditory canal. A double-blind, cross-over study in patients with Meniere's disease is now in progress with Institutional Review Board (IRB) approval, which will be reported at a later date. This preliminary study has shown that intratympanic steroids may affect the symptoms of hearing loss and tinnitus in patients with various inner ear problems. Patients with Meniere's disease appear to respond in the highest percentage of cases. Hopefully, additional research will suggest the appropriate drugs which can be used to treat inner ear disease. Direct application of the drug to the round window membrane may increase the concentration in the inner ear fluids, thus avoiding the systemic effects.
向鼓室内滴注得宝松(80毫克/立方厘米)、地塞米松眼药水(1毫克/立方厘米)或地塞米松静脉注射液(4毫克/立方厘米)可使某些梅尼埃病、自身免疫性内耳疾病和突发性感音神经性聋患者的耳蜗功能得到改善。耳鸣改善率为47%,最常见于梅尼埃病患者(15例中的9例;60%)。41%的患者记录到听阈提高大于10分贝或标准差大于15%(听阈平均提高:15分贝;标准差:24%)。耳鸣和双侧感音神经性听力损失(即老年性聋)患者未从该治疗中获益。在用鼓室内药物治疗之前,采用激光辅助鼓膜切开术并进行中耳探查,利用耳内镜确定圆窗龛的状态并去除黏膜皱襞,有助于使圆窗膜便于局部滴注药物。在直视下将明胶海绵放入圆窗龛,并在鼓膜中使用文丘里管,似乎是将药物输送到内耳液的一种令人满意的方法。医生可通过该管将药物注入中耳,或者患者可在家中自行治疗,将药物置于外耳道。一项针对梅尼埃病患者的双盲交叉研究目前正在进行中,并已获得机构审查委员会(IRB)的批准,后续将予以报道。这项初步研究表明,鼓室内注射类固醇可能会影响各种内耳问题患者的听力损失和耳鸣症状。梅尼埃病患者的反应率似乎最高。希望更多的研究能找到可用于治疗内耳疾病的合适药物。将药物直接应用于圆窗膜可能会增加内耳液中的药物浓度,从而避免全身效应。